Cytiva

Cytiva is a biotechnology and life sciences company that provides technologies used to discover, develop, manufacture, and quality-control biologic medicines. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, academic laboratories, research institutes, and organizations involved in vaccine, cell therapy, gene therapy, and other advanced-therapy development. The company is part of Danaher Corporation and operates within Danaher's biotechnology activities. The Cytiva brand was created in 2020 when Danaher acquired the biopharmaceutical business of General Electric. The acquired business had previously operated under GE Healthcare Life Sciences and brought together established capabilities in chromatography, filtration, cell culture, bioreactor systems, process development, laboratory instruments, consumables, and related services. Danaher positioned the new business as a dedicated supplier to the biopharmaceutical industry rather than as a general medical-equipment manufacturer. The name Cytiva combines a reference to cells with a suffix intended to suggest capability and action. Cytiva's central role in the biopharmaceutical value chain is to provide the equipment, single-use components, resins, membranes, software, and process expertise needed to move from laboratory-scale research to commercial manufacturing. Its technologies support upstream activities such as cell cultivation and fermentation, downstream activities such as clarification, filtration, and chromatography, and process monitoring and control. The company also supplies solutions for viral-vector production, cell and gene therapy workflows, and other emerging modalities. Its offerings are typically integrated into larger manufacturing processes, making validation, reproducibility, regulatory documentation, and technical support important parts of the value proposition. Among its best-known product families is ÄKTA, a platform for laboratory and process-scale protein purification and chromatography. Cytiva also supplies chromatography resins and columns, filtration and single-use assemblies, bioreactor and cell-culture systems, and process-development tools. These products are used for monoclonal antibodies, recombinant proteins, vaccines, plasma-derived products, viral vectors, and other biologic materials. The company serves both research and production environments, with products ranging from laboratory consumables to equipment designed for large-scale manufacturing. Cytiva expanded its advanced-therapy capabilities through the acquisition of Precision Nanosystems in 2021. Precision Nanosystems is associated with technologies for the development and manufacture of genetic medicines, including systems used in nucleic-acid delivery and related workflows. In 2023, Pall Corporation was merged with Cytiva to form a broader biotechnology group within Danaher. The combination strengthened Cytiva's position in filtration, fluid-management, single-use manufacturing, and bioprocessing. Danaher stated at that time that the combined organization employed more than 16,000 associates across over 40 countries. Cytiva competes in a specialized and highly regulated market alongside suppliers such as Sartorius, Merck's MilliporeSigma business, Thermo Fisher Scientific, and other providers of bioprocess equipment, consumables, and analytical technologies. Its positioning emphasizes end-to-end process support, global manufacturing and service infrastructure, application expertise, and products designed to help customers scale biological processes while maintaining quality and regulatory control. As a privately held Danaher subsidiary, Cytiva does not have a separate public stock listing or independently reported public-market ticker.

Cytiva was created in 2020 as the new brand for the biopharmaceutical business acquired by Danaher from General Electric. Before the transaction, the business operated within GE Healthcare and was known for supplying technologies used in bioprocessing and biomanufacturing. The acquisition gave Danaher a substantial platform in the development and production of biologic medicines, including vaccines, therapeutic proteins, and emerging cell and gene therapies. The acquired operations carried a portfolio developed over many years around the needs of biopharmaceutical manufacturers. Its capabilities included chromatography systems and purification media, filtration technologies, cell-culture products, bioreactors, single-use manufacturing components, process-development tools, and related services. These technologies address multiple stages of production. Upstream systems support the growth of cells or microorganisms that produce a desired biological substance. Downstream systems separate and purify that substance, while filtration, containment, monitoring, and process-control products help manufacturers maintain quality and consistency. The Cytiva name marked a strategic separation from GE's broader healthcare identity. Danaher presented Cytiva as a focused biotechnology company serving customers across research, process development, clinical manufacturing, and commercial production. The business became part of Danaher's biotechnology activities alongside other life sciences and bioprocessing companies. Its commercial model combines instruments and production equipment with recurring consumables, including chromatography resins, membranes, bags, tubing, filters, and other single-use products. Application support, validation assistance, maintenance, and process expertise are also important to the relationship with customers. In June 2021, Cytiva acquired Precision Nanosystems. The transaction broadened the company's presence in technologies associated with genetic medicines and advanced therapies. Precision Nanosystems added capabilities relevant to nucleic-acid delivery and the development of cell and gene therapy processes, areas in which manufacturers require specialized tools for both research and scalable production. Cytiva's corporate scope expanded again in 2023 when Danaher merged Pall Corporation with Cytiva. Pall had long supplied filtration, separation, fluid-management, and single-use technologies to industrial and life sciences customers. Combining Pall with Cytiva strengthened the portfolio available to biopharmaceutical manufacturers and created a broader biotechnology group within Danaher. At the time, the combined Cytiva organization was described as employing more than 16,000 associates in more than 40 countries. The business operates in a market shaped by the growth of biologic medicines and by strict regulatory requirements. Manufacturers need processes that can be scaled from laboratory work to commercial output while preserving product quality, sterility, traceability, and reproducibility. Cytiva therefore competes not only on individual instruments or consumables, but also on the compatibility of its product portfolio, technical services, global supply network, and ability to support customers through different phases of a therapy's lifecycle. Cytiva remains a wholly owned Danaher business rather than a separately listed company. Its current scope centers on bioprocessing and life sciences, with particular relevance to protein purification, filtration, cell culture, single-use manufacturing, viral-vector and genetic-medicine workflows, and other technologies supporting the production of biologic therapies.

1. 2023Pall Corporation merges with Cytiva

   Danaher combined Pall Corporation and Cytiva into a broader Biotechnology Group, increasing the group's capabilities in filtration, single-use systems, fluid management, and bioprocessing.

   Source
2. 2021Precision Nanosystems joins Cytiva

   Cytiva acquired Precision Nanosystems, adding technologies relevant to nucleic-acid delivery and cell and gene therapy development.

   Source
3. 2020Danaher acquires GE's biopharmaceutical business

   Danaher acquired GE's biopharmaceutical business in a transaction reported at approximately $21.4 billion and rebranded the business as Cytiva. Regulatory approval involved the divestiture of certain biotechnology assets to address competition concerns.

   Source

A global bioprocessing partner supplying integrated tools, consumables, and services for the research, development, manufacture, and quality control of biologic medicines.

• ÄKTA chromatography systemsChromatography

  ÄKTA is a family of liquid-chromatography systems used to purify proteins and other biomolecules. Configurations span laboratory research, process development, and larger-scale bioprocess applications. The systems are commonly paired with Cytiva chromatography columns, resins, and software to support method development, purification, and process scale-up.

• Chromatography resins and columnsBioprocess consumables

  Cytiva supplies chromatography media, prepacked columns, and related purification components for separating and refining biological molecules. These products support techniques such as affinity, ion-exchange, and size-exclusion chromatography and are used in research, process development, and manufacturing of therapeutic proteins, vaccines, and other biologics.

• Filtration and single-use technologiesBioprocess equipment and consumables

  The portfolio includes membrane filtration, depth filtration, sterile filtration, bags, tubing, connectors, and other single-use components. These technologies are used to clarify, concentrate, sterilize, transfer, and contain process fluids while reducing cleaning and cross-contamination requirements in biopharmaceutical production.

• Cell-culture and bioreactor solutionsCell culture

  Cytiva provides products for growing cells used to produce biologic medicines. The range includes cell-culture media, culture vessels, bioreactor systems, and associated process components. These offerings are intended to help customers move from exploratory laboratory work toward controlled, scalable manufacturing processes.

• Cell and gene therapy technologiesAdvanced-therapy manufacturing2021

  Cytiva supplies workflow technologies for advanced therapies, including tools associated with viral-vector production, nucleic-acid delivery, and cell-processing applications. The acquisition of Precision Nanosystems strengthened this area, particularly for genetic-medicine development and manufacturing workflows.

• 2023Combine Pall Corporation with CytivaStrategy

  Danaher had complementary bioprocessing capabilities in Cytiva and Pall Corporation, particularly in chromatography, filtration, fluid management, and single-use manufacturing.

  What changed. Danaher merged Pall Corporation with Cytiva to create a broader Biotechnology Group.

  Aftermath. The combined organization offered a wider set of technologies and was reported to employ more than 16,000 associates in over 40 countries.

  Source
• 2020Create Cytiva through the GE biopharmaceutical acquisitionM&A

  Danaher sought to expand its biotechnology platform by acquiring GE's biopharmaceutical business, which supplied technologies for the development and manufacture of vaccines, therapeutics, and other biological products.

  What changed. Danaher completed the acquisition and introduced Cytiva as the brand for the acquired business. To obtain regulatory clearance, certain biotechnology assets were divested to Sartorius.

  Aftermath. Cytiva became a major operating business within Danaher's biotechnology activities and continued to expand its bioprocessing and advanced-therapy portfolio.

  Reported transaction value. $21.4 billion (2020)

  Source

• 2023Pall Corporation and Cytiva combine within Danaher's biotechnology group

  Pall Corporation was merged with Cytiva, creating a larger biotechnology group with expanded capabilities in filtration, fluid management, single-use technologies, and bioprocessing.

  M&A
  Source
• 2021Cytiva acquires Precision Nanosystems

  Cytiva acquired Precision Nanosystems to add capabilities relevant to genetic medicines, nucleic-acid delivery, and cell and gene therapy development.

  M&A
  Source
• 2020Danaher completes acquisition of GE biopharmaceutical business and launches Cytiva

  Danaher acquired GE's biopharmaceutical business and established Cytiva as the operating brand for the business. The transaction expanded Danaher's biotechnology platform and brought together technologies for bioprocess development and manufacturing.

  M&AProduct launch
  Source

1. Cytiva official website
2. Danaher Corporation